ELVN beat EPS expectations by 27.67%
Nov 16, 2025, 11:36 AM
0.00%
What does ELVN do
Enliven Therapeutics, a clinical stage precision oncology company based in Boulder, Colorado, went public on March 12, 2020. It is developing ELVN-001 for chronic myeloid leukemia and ELVN-002 for HER2 mutations.
Enliven Therapeutics (ELVN) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Enliven Therapeutics's actual EPS was -$0.32, beating the estimate of -$0.44 per share, resulting in a 27.67% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.